Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer
Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Surgical resection and adjuvant therapy has become the main treatment for
resectable colorectal cancer. Treatment with current strategies, however,recurrent rate is
high for stage IIIC or R0 resected stage IV. The efficacy and safety of maintenance therapy
with capecitabine is still unknown.
PURPOSE: This single arm study is exploring surgical resection and adjuvant chemotherapy
followed by maintenance therapy with capecitabine to see the efficacy and safety, then to
investigate the effect of maintenance therapy for stage IIIC or R0 resected stage IV
colorectal cancer.